Nigeria

Mosquito nets treated with new ingredients show greater reductions in malaria than standard insecticide-treated nets.

The New Nets Project was established with the goal of making the latest resistance breaking net technology more widely available to malaria programs throughout Africa. As well as managing the rapid deployment of new nets to partner countries and negotiating a volume guarantee to reduce prices, the New Nets Project partners oversee randomized control trials and pilots. The evidence gathered from these will be used to ascertain the impact and cost-effectiveness of the nets and support an appropriate policy recommendation from the World Health Organization (WHO). The New Nets Project is co-funded by Unitaid and The Global Fund, with complementary funding provided by the Bill & Melinda Gates Foundation and USAID. The project is led by IVCC. This report shares interim findings from the five observational studies led by PATH.

Working across 24 countries in sub-Saharan Africa as well as Cambodia and Colombia, the PMI VectorLink Project is working with national malaria programs to plan and implement safe, cost-effective, and sustainable IRS, ITN, and other life-saving malaria vector control interventions with the overall goal of reducing the burden of malaria.PMI VectorLink works with national malaria programs to compile, analyze, and visualize relevant existing data to guide vector control decisions and strategies. National program and partner datasets are integrated for review and analysis, including entomological, epidemiological, intervention coverage, and climatological data. PMI VectorLink addresses barriers to using existing data through dashboards that make relevant data more easily accessible, digestible, timely, and action-oriented.In Nigeria, through a PATH-led integrated data analytics and visualization activity, PMI VectorLink is using data to mitigate the impact of insecticide resistance. This case study explores the opportunity and challenge of using new nets formulated to combat insecticide resistance, and how data is assisting decision-making.The PMI VectorLink project is being led by Abt Associates in partnership with Population Services International and PATH along with the support of Liverpool School of Tropical Medicine, Malaria Consortium, Innovative Vector Control Consortium, McKinsey & Company, Inc., EnCompass LLC, BAO Systems LLC, Digital Globe, and Dimagi, Inc.

During the COVID-19 pandemic, governments around the world have rapidly introduced policies to mitigate service disruptions to RMNCAH,N care using innovative adaptations such as telehealth or task shifting. As part of our ongoing COVID-19 Essential Health Services Policy Tracker project supported by the Bill & Melinda Gates Foundation, PATH developed a set of briefs that explore in detail the service delivery adaptations outlined in pandemic-era government policies in five countries (Burkina Faso, Ethiopia, India, Nigeria, and Pakistan) to equip country leaders, donors, and advocates with tactics for maintaining essential health services through the pandemic and beyond.(French translation available for brief on Burkina Faso)

PATH is a leader in adapting health innovations with and for women across systems, populations, and geographies. This brief outlines PATH's vision, approach, and areas of expertise in Sexual and Reproductive Health.

The New Nets Project, a partnership funded by Unitaid and the Global Fund and led by IVCC, aims to accelerate the scale-up of next-generation, dual-active ingredient ITNs and to provide National Malaria Control Programs, donors, and implementers with clear evidence of their impact on malaria burden.

This brief summarizes the experience and capabilities of the PATH HPV Vaccine Team. For decades, PATH has been at the forefront of evidence-based strategies from HPV vaccine research and delivery to cervical cancer screening and treatment to ensure we best meet the needs and realities of these countries for the greatest health impact.

This brief summarizes the experience and capabilities of the PATH Cervical Cancer Team. For decades, PATH has been at the forefront of evidence-based strategies from HPV vaccine research and delivery to cervical cancer screening and treatment to ensure we best meet the needs and realities of these countries for the greatest health impact.

While most people with COVID-19 develop only mild or moderate respiratory tract disease, approximately 20 percent develop severe or critical disease that requires oxygen therapy to support breathing. In many health facilities across low- and middle-income countries, however, oxygen therapy—including diagnosis, generation, and delivery equipment—is not reliably available.Many of the tools and capabilities needed to overcome these barriers already exist across different global health and implementing organizations, manufacturers and suppliers, and country governments. To ensure that those who need respiratory care support due to COVID-19, or beyond, receive it, immediate steps are necessary to coordinate the global response that prioritizes reliable access to oxygen.This fact sheet offers an overview of the project to support countries in planning and executing a respiratory care plan to meet the demands of COVID-19, as well as pursue strategies to help prioritize and improve access to oxygen therapy and other essential equipment involved in respiratory care as an integral part of health systems strengthening, beyond the pandemic response.